Deferred Tax Assets, Valuation Allowance of Cogent Biosciences, Inc. from 31 Dec 2017 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Cogent Biosciences, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2017 to 31 Dec 2025.
  • Cogent Biosciences, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $311,030,000, a 42% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

Cogent Biosciences, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $311,030,000 +$92,478,000 +42% 31 Dec 2025 10-K 17 Feb 2026 2025 FY
Q4 2024 $218,552,000 +$61,482,000 +39% 31 Dec 2024 10-K 17 Feb 2026 2025 FY
Q4 2023 $157,070,000 +$67,526,000 +75% 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q4 2022 $89,544,000 +$42,857,000 +92% 31 Dec 2022 10-K 26 Feb 2024 2023 FY
Q4 2021 $46,687,000 +$18,888,000 +68% 31 Dec 2021 10-K 14 Mar 2023 2022 FY
Q4 2020 $27,799,000 -$10,688,000 -28% 31 Dec 2020 10-K 15 Mar 2022 2021 FY
Q4 2019 $38,487,000 +$9,590,000 +33% 31 Dec 2019 10-K 16 Mar 2021 2020 FY
Q4 2018 $28,897,000 +$12,286,000 +74% 31 Dec 2018 10-K 26 Mar 2020 2019 FY
Q4 2017 $16,611,000 31 Dec 2017 10-K 28 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.